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Background/Aims: This study was performed to evaluate the efficacy of direct-acting antivirals 
(DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) 
and to investigate the risk factors associated with HCC recurrence. 
Methods: A total of 100 patients with HCV-related HCC, who were treated with DAAs between 
May 2015 and December 2016, were recruited from seven university hospitals in Korea. Claim 
data of 526 patients with HCC obtained from the Health Insurance Review and Assessment Ser-
vice in South Korea were used for external validation of the results. 
Results: Among the 100 patients, 88% achieved a sustained virological response (SVR) 12 
weeks after the end of DAA therapy (SVR12), and 37% experienced HCC recurrence after DAA 
therapy. Short last HCC treatment durability (<12 months) before DAA commencement was inde-
pendently associated with HCC recurrence (hazard ratio [HR], 2.89; p=0.011). In the nationwide 
validation cohort, 20.3% of the patients experienced HCC recurrence. The last HCC treatment 
with a noncurative method, a short last HCC treatment durability (<12 months), and a longer total 
duration of HCC treatment (≥18 months) were independently related with HCC recurrence (HR 
3.73, p<0.001; HR 3.34, p<0.001; and HR 1.74, p=0.006; respectively). 
Conclusions: DAA therapy showed an acceptable SVR12 rate in patients with HCV-related 
HCC. Short last HCC treatment durability (<12 months) was associated with HCC recurrence 
after DAA therapy. This finding suggests that the last HCC treatment durability is an important 
predictor of HCC recurrence after DAA therapy. (Gut Liver 2021;15:410-419)
Key Words: Carcinoma, hepatocellular; Antiviral agents; Risk factors; Hepatitis C, chronic; Re-
currence
INTRODUCTION
Chronic infection with hepatitis C virus (HCV) is a 
well-known risk factor for liver cirrhosis and hepatocel-
lular carcinoma (HCC), which is one of the most common 
and fatal malignancies globally.1,2 Direct-acting antivirals 
(DAAs) exhibit an excellent efficacy against HCV.3-6 While 
the pegylated interferon plus ribavirin therapy approved 
in 2001 shows a sustained virological response (SVR) of 
42% to 46% in genotype 1 and 76% to 82% in genotypes 2 
or 3,7,8 the success rate of DAA therapy is over 86%, even 
in patients with a decompensated or an advanced liver 
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disease.9,10 Consequently, DAAs have become an indis-
pensable element of hepatitis C treatment. Recently, the 
World Health Organization has set a goal to treat 80% of 
the global hepatitis C cases, and reduce annual deaths due 
to viral hepatitis by 35%, by 2030.11 It is important to eluci-
date reasonable study outcomes to reduce the uncertainty 
surrounding DAA therapy, and to allow more patients to 
be treated, including patients with HCV-associated HCC. 
Reportedly, patients with HCC are more resistant to 
DAA therapy than those without HCC.12-14 SVR rates of 
74.4% to 79% and 88% to 91.1% were recorded in American 
patients with and without HCC, respectively.13,14 However, 
little is known about the efficacy of DAA therapy in the 
Asian population. Recent studies have reported unexpect-
edly high rates of HCC recurrence after a successful DAA 
treatment.15-17 While a meta-analysis showed no difference 
in HCC recurrence following DAA or interferon therapy af-
ter adjusting for study follow-up time and patient age,18 the 
issue raises an uncertainty about the  appropriate timing of 
treatment of HCV-infected patients with a history of HCC. 
Therefore, it is important to identify risk factors associated 
with HCC recurrence in the DAA-treated patients. 
The aim of this study was to evaluate the therapeutic 
efficacy of DAAs in Asian patients with a history of HCV-
induced HCC, and investigate the risk factors for HCC 
recurrence after DAA therapy.
MATERIALS AND METHODS
1. Patient selection
We retrospectively recruited 100 patients with HCV-
infected HCC from seven university hospitals in South 
Korea. Patients who achieved complete response (CR) af-
ter HCC treatment and started the DAA therapy between 
August 2015 and December 2016 were enrolled. Chronic 
hepatitis C was defined as the presence of the anti-HCV 
antibody and HCV RNA for more than 6 months. HCC 
was diagnosed if the tumor had a minimum diameter ≥1 
cm, and if typical features of HCC (arterial phase hyperen-
hancement, washout in the portal venous or delayed phase, 
threshold growth, and capsule appearance) were observed 
using multiphase computed tomography and/or magnetic 
resonance imaging. If these criteria were present but there 
was a lack of a diagnostic certainty, a liver biopsy was per-
formed to confirm the diagnosis of HCC.19 Patients were 
excluded if they met any of the following criteria: evidence 
of autoimmune hepatitis or viral co-infection, such as 
those with the hepatitis B virus or the human immunode-
ficiency virus; alcohol consumption >210 g per week for 
males and >140 g per week for females; no CR after HCC 
treatment prior to DAA therapy; liver transplantation be-
fore DAA therapy; no tumor status assessment after start-
ing DAA therapy; and/or treatment with interferon as part 
of DAA therapy. The patients were followed-up until HCC 
recurrence or until January 2018.
For external validation, we used data from patients with 
an HCV-infected HCC from the Korean Health Insurance 
Review and Assessment Service (HIRA)20 (Supplementary 
Fig. 1). HIRA data, which is generated in the process of 
reimbursing healthcare providers under National Health 
Insurance, contains specific, yet comprehensive informa-
tion on the relevant healthcare services, such as proce-
dures, surgeries, examinations, and treatment, including 
prescriptions and socio-demographic characteristics of 
patients. In South Korea, National Health Insurance cov-
ers approximately 98% of the total population. Moreover, 
all healthcare providers are required to be covered under 
the National Health Insurance, which is based on fee-
for-services.20 Subjects with HCC (C220 and C229) who 
were prescribed DAA therapy (638101ATB [daclatas-
vir], 638001ACH [asunaprevir], 644401ATB [sofosbu-
vir], 645800ATB [ledipasvir/sofosbuvir], 223604ACH, 
223601ACH, and 223601ACH [ribavirin]) between August 
2015 and December 2016 were extracted from the HIRA 
database using the International Classification of Diseases 
(10th edition).21,22 The exclusion criteria were as follows: 
autoimmune hepatitis (K75.4) or viral co-infection, in-
cluding those with the hepatitis B (B18.0, B18.10, B18.18, 
B18.1, and Z22.5) and the human immunodeficiency virus 
(Z21.X, Z86.X, B20.X, B21.X, B22.X, B23.X, and B24.X); 
liver transplantation before DAA therapy; history of DAA 
therapy before or during HCC treatment. HCC recur-
rence was defined as reinitiation of HCC treatment after 
DAA therapy. The patients were followed-up until HCC 
recurrence or until December 2016. The study protocol 
was approved by the Institutional Review Board of the 
Ajou University Hospital (IRB number: AJIRB-MED-
MDB-17-031).
2. Definitions
Baseline characteristics, including age, liver function, 
and the HCV RNA level, were documented at the start of 
the DAA therapy. HCC treatment duration was defined as 
the time between the initial HCC treatment and the last 
HCC treatment before a DAA therapy. Last HCC treat-
ment durability was defined as the time between the final 
HCC treatment and the start of a DAA therapy. HCC 
recurrence time was calculated from the start of a DAA 
treatment. The SVR was determined 12 weeks after the end 
of a DAA treatment (SVR12). CR acquisition was defined 
according to modified RECIST criteria, disappearance of 
Gut and Liver, Vol. 15, No. 3, May 2021
412  www.gutnliver.org
any intratumoral arterial enhancement in all target lesions 
on follow-up image study.23
3. Statistics
Data management and analysis were performed us-
ing the R statistical software (version 3.3.4; R Core Team 
[2014]; R: A language and environment for statistical 
computing; R Foundation for Statistical Computing, Vi-
enna Austria; http://www.R-project.org/). Differences 
with p<0.05 were considered statistically significant. All 
statistical analyses were performed using two-tailed tests: 
continuous variables were analyzed using the independent 
samples t-test while categorical data were compared using 
the Pearson chi-square test or the Fisher exact test. Cumu-
lative probabilities of HCC recurrence were assessed by 
the Kaplan-Meier analysis. The Cox proportional hazard 
model was used to identify factors associated with HCC 
recurrence.
RESULTS
1. Baseline characteristics of the multicenter cohort 
The mean age of the subjects was 69.2±8.4 years, and 
67% of them were male. The patients were the most com-
monly infected with the HCV genotype 1b (66%), followed 
by the genotype 2 (32%), genotype 1a (1%), and genotype 
4 (1%). Cirrhosis and diabetes mellitus were diagnosed in 
79% and 33% of the patients, respectively. HCC in BCLC 
(Barcelona Clinic Liver Cancer) stages B or C was detected 
in 11% of the cohort, whereas modified Union for Inter-
national Cancer Control stage III or IV disease was found 
in 12% of the patients; 23% of the subjects had previously 
received an interferon based therapy (Table 1). 
Among the 100 subjects with an HCV-related HCC, 24 
underwent radiofrequency ablation (RFA) therapy, 21 were 
treated with a transarterial chemoembolization (TACE), 19 
experienced liver resection, two underwent radiation ther-
apy, one received a transarterial radioembolization, and 
33 were treated with multimodal therapy. Regarding the 
modality of the last HCC treatment, TACE (36%) was the 
most frequently used, followed by RFA (33%), liver resec-
tion (21%), combination therapy (6%), and other therapies 
(4%). The median follow-up period after a DAA treatment 
start was 15.8 months (range, 4.4 to 29.9 months).
2. Efficacy of DAA therapy in patients with HCC
The efficacy of DAA therapy in patients with HCC is 
summarized in Fig. 1. Among the 100 patients in the mul-
ticenter cohort, 88 achieved SVR12 with DAA therapy. 
Even in those who experienced HCC recurrence, the 
SVR12 acquisition rate was as high as 86.5% (32/37). 
SVR12 was achieved by 86.1% (68/79) of patients with 
liver cirrhosis and by 95.2% (20/21) of those without it. 
The SVR12 rate was 87.9% (58/66) and 87.5% (28/32) with 
the genotypes 1b and 2, respectively. The only patient with 
genotype 1a and the only patient with genotype 4 acquired 
SVR12. Of the 36 patients who started the DAA therapy 
within 6 months of the last HCC treatment, 33 (91.7%) ob-
tained SVR12. The SVR12 rate did not significantly differ 
between the groups (Fig. 1). 
Table 1. Baseline Characteristics of 100 Multicenter Cohort Subjects
Characteristics Value (n=100)
Age, yr 69.2±8.4
Male sex 67 (67)
Diabetes mellitus 33 (33)
Liver cirrhosis 79 (79)
Child-Pugh
   A 95 (95)
   B 4 (4)
   C 1 (1)
BCLC stage
   0 34 (34)
   A 55 (55)
   B 7 (7)
   C 4 (4)
mUICC stage
   I 48 (48)
   II 40 (40)
   III 10 (10)











   1a  1 (1)
   1b 66 (66)
   2 32 (32)
   4 1 (1)
Previous interferon-based treatment 23 (23)
HCV RNA, log10 IU/mL 5.42±0.92
DAA combination
   Daclatasvir+asunaprevir 59 (59)
   Sofosbuvir+ribavirin 33 (33)
   Ledipasvir/sofosbuvir 8 (8)
Data are presented as the mean±SD or number (%). 
BCLC, Barcelona Clinic Liver Cancer; mUICC, modified Union for 
International Cancer Control; AST, aspartate aminotransferase; ALT, 
alanine aminotransferase; INR, international normalized ratio; AFP, 
alpha-fetoprotein; HCV, hepatitis C virus; DAA, direct-acting antiviral 
agent.
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3. Details of 37 patients with HCC recurrence after 
DAA therapy
During the median follow-up period of 15.8 months 
(range, 4.4 to 29.9 months), 37% of the study subjects ex-
perienced HCC recurrence; the 1-year and 2-year cumula-
tive recurrence rate was 28.4% and 61.3%, respectively. The 
median number and size of the recurrent tumors were 1 
(range, 1 to 6) and 1.25 cm (range, 0.8 to 5.7 cm), respec-
tively. Regarding the pattern of recurrence, a new intrahe-
patic recurrence (62.2%) was most commonly detected, 
followed by a marginal recurrence (16.2%), and a marginal 
recurrence combined with a new intrahepatic recurrence 
(5.4%). Extrahepatic recurrence was not observed. The 
majority of the patients (67.6%) were treated with TACE, 
16.2% underwent RFA, while 5.4% received RFA as well 
as TACE. Radiation therapy, TACE followed by radiation 
therapy, and TACE followed by sorafenib were used in 2.7% 
of the cases each. After HCC recurrence, 58.8% of the pa-
tients showed CR while 14.7% obtained a partial response. 
Stable and progressive disease were observed in 5.9% and 
20.6% of the cases, respectively.
4. Risk factors for HCC recurrence in the multicenter 
cohort
According to the univariate analysis, low platelet levels 
(p=0.040), HCC treatment with a noncurative method 
such as TACE, transarterial radioembolization, hepatic 
artery infusion chemotherapy, sorafenib and radiotherapy 
(p<0.001), last HCC treatment with a noncurative method 
(p<0.001), HCC treatment duration more than 18 months 
(p=0.009), and last HCC treatment durability less than 12 
months (p=0.006) were related to HCC recurrence. In con-
trast, age (p=0.127), liver cirrhosis (p=0.159), and SVR12 
(p=0.934) were not associated with HCC recurrence (Table 
2). Multivariate Cox regression analysis showed that short 
last HCC treatment durability (<12 months) was only in-
dependently associated with HCC recurrence in patients 
with the HCV-related HCC after the DAA treatment (haz-
ard ratio [HR], 2.89; 95% confidence interval [CI], 1.27 to 
6.59; p=0.011) (Table 3, Fig. 2).
In subgroup analysis with patients who were treated 
with curative modality, mean HCC treatment durability 
(p=0.046) and last HCC treatment durability less than 12 
months (p=0.036) were related to HCC recurrence. In age- 
and sex-adjusted multivariate Cox regression analysis, 
the relationship between last HCC treatment durability 
and HCC recurrence showed no statistical significance 
(p=0.058) (Supplementary Table 1).
5. External validation using the HIRA cohort
A total of 526 patients with HCV-related HCC and 
treated with DAAs were identified in the HIRA cohort. 
Baseline characteristics of the validation cohort have been 
listed in Table 4. The mean age of the subjects was 66.9±9.6 
years, and 63.7% of them were male. Cirrhosis and dia-
betes were diagnosed in 87.1% and 70.5% of the cases, 
respectively, and 8% of the subjects had received a previ-
ous interferon based therapy. Among the 526 patients, 107 
(20.3%) experienced HCC recurrence.
In the univariate analysis, HCC treatment with a non-
curative method, the last HCC treatment with a noncura-
tive method, a long duration of the HCC treatment (≥18 
months), and short last HCC treatment durability before 
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Fig. 1. Rates of the SVR 12 weeks after the end of DAA therapy (SVR12) in patients with hepatitis C virus-related HCC.
SVR, sustained virological response; DAA, direct-acting antiviral agent; HCC, hepatocellular carcinoma; CR, complete response.
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rence (Table 5). Moreover, the multivariate Cox regression 
analysis showed that the last HCC treatment with a non-
curative method (HR, 3.73; 95% CI, 1.87 to 7.43; p<0.001), 
HCC treatment duration ≥18 months (HR, 1.74; 95% CI, 
1.16 to 2.60; p=0.006), the last HCC treatment durability 
<12 months (HR, 3.34; 95% CI, 1.95 to 5.71; p<0.001) were 
independently associated with HCC recurrence (Table 5, 
Fig. 3).







Age, yr 68.7±8.9 69.9±7.4 0.127
Male sex 42 (66.7) 25 (67.6) 0.926
Diabetes mellitus 22 (34.9) 11 (29.7) 0.594
Liver cirrhosis 47 (74.6) 32 (86.5) 0.159
Child-Pugh 0.377
  A 60 (95.2) 35 (94.6)
  B 3 (4.8) 1 (2.7)
  C 0 1 (2.7)
Hemoglobin, g/dL 13.0±1.6 12.9±1.3 0.238
Platelet, ×103/μL 121.9±64.5 95.4±38.1  0.040†
Total bilirubin, mg/dL 1.06±0.57 1.11±0.53 0.399
Albumin, g/dL 3.7±0.5 3.6±0.4 0.208
AST, IU/L 62.4±30.7 66.0±37.0 0.831
ALT, IU/L 46.9±30.0 45.9±32.7 0.570
Creatinine, mg/dL 0.81±0.20 0.77±0.15 0.145
INR 1.07±0.19 1.10±0.18 0.823
AFP, ng/mL 30.4±65.0 50.1±90.0 0.405
HCV RNA, log10 IU/mL 5.42±0.99 5.42±0.79 0.091
Genotype 0.348
   1a 1 (1.6) 0
   1b 44 (69.8) 22 (59.5)
   2 18 (28.6) 14 (37.8)
   4 0 1 (2.7)
SVR 12 56 (88.9) 32 (86.5) 0.934
BCLC stage 0.248
   0 23 (36.5) 11 (29.7)
   A 35 (55.6) 20 (54.1)
   B 2 (3.2) 5 (13.5)
   C 3 (4.8) 1 (2.7)
mUICC stage 0.064
   I 34 (54.0) 14 (37.8)
   II 24 (38.1) 16 (43.2)
   III 3 (4.8) 7 (18.9)
   IV 2 (3.2) 0
HCC treatment using noncurative modality* 27 (42.9) 29 (78.4) <0.001†
Last HCC treatment using noncurative modality* 20 (31.7) 26 (70.3) <0.001†
HCC treatment duration (≥18 mo) 12 (19.0) 16 (43.2) 0.009†
Last HCC treatment durability (<12 mo) 32 (50.8) 29 (78.4) 0.006†
Last HCC treatment durability, day 528.7±661.9 271.5±319.6 0.009†
DAA combination 0.417
   Daclatasvir+asunaprevir 39 (61.9) 20 (54.1)
   Sofosbuvir+ribavirin 18 (28.6) 15 (40.5)
   Ledipasvir/sofosbuvir 6 (9.5) 2 (5.4)
Data are presented as the mean±SD or number (%). 
HCC, hepatocellular carcinoma; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; AFP, 
alpha-fetoprotein; HCV, hepatitis C virus; SVR, sustained virologic response; BCLC, Barcelona Clinic Liver Cancer; mUICC, modified Union for In-
ternational Cancer Control; DAA, direct-acting antiviral agent.
*Noncurative modality included transarterial chemoembolization, transarterial radioembolization, hepatic artery infusion chemotherapy, sorafenib 
and radiotherapy; †Statistically significant, p<0.05.
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DISCUSSION
In the present study, short last HCC treatment durabil-
ity before a DAA therapy (<12 months) was an indepen-
dent predictor of HCC recurrence in both the multicenter 
cohort and the nationwide cohort from the Korean HIRA 
database. To the best of our knowledge, this is the first 
study to evaluate the risk factors for predicting HCC recur-
rence after the DAA therapy in Korean patients with HCV-
related HCC. 
Short last HCC treatment durability (<12 months) was 
the only common independent risk factor for HCC re-
currence in the both multicenter cohort and nationwide 
HIRA cohort. The last HCC treatment with a noncurative 
method and a long total duration of the HCC treatment 
(≥18 months) prior to the DAA therapy were independent 
risk factors in the HIRA cohort, but not in the multicenter 
cohort. This discrepancy may be explained by differences 
in the two study populations. HIRA data, as national 
claims data, does not include information on the HCC 
stage or radiological findings, making it difficult to con-
firm CR in patients. Therefore, the validation cohort was 
more heterogeneous than the test cohort, which may have 
contributed to different risk factors for HCC recurrence in 
the two study groups. 
Table 4. Baseline Characteristics of 526 Subjects in the HIRA Cohort
Characteristics Value (n=526)
Age, yr 66.9±9.6
Male sex 335 (63.7)
Diabetes mellitus 371 (70.5)
Liver cirrhosis 458 (87.1)
Previous interferon-based treatment 42 (8.0)
DAA combination
   Daclatasvir+asunaprevir 327 (62.2)
   Sofosbuvir+ribavirin 127 (24.1)
   Ledipasvir/sofosbuvir  61 (11.6)
   Sofosbuvir+daclatasvir 11 (2.1)
HCC treatment modality before DAA therapy
   Resection  3 (0.6)
   RFA 135 (25.7)
   TACE 226 (43.0)
   Multi-modality 146 (27.8)
   Other therapies 16 (2.9)
Last HCC treatment modality before DAA therapy
   Resection  4 (0.8)
   RFA 185 (35.2)
   TACE 296 (56.3)
   Combination treatment 17 (3.2)
   Other therapies 24 (4.6)
Data are presented as the mean±SD or number (%). 
HIRA, Health Insurance Review and Assessment; DAA, direct-acting 
antiviral agent; HCC, hepatocellular carcinoma; RFA, radiofrequency 
ablation; TACE, transarterial chemoembolization.
Table 3. Multivariate Analysis for Risk Factors for HCC Recurrence in 
the Multicenter Cohort
Multivariate analysis HR 95% CI p-value
Platelet (<10×103/μL) 1.74 0.86–3.52 0.119
HCC treatment with noncurative modality* 1.78 0.49–6.38 0.374
Last HCC treatment with noncurative 
modality*
2.18 0.69–6.82 0.179
HCC treatment duration (≥18 mo) 1.97 0.99–3.88 0.050
Last HCC treatment durability (<12 mo) 2.89 1.27–6.59 0.011†
HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence in-
terval. 
*Noncurative modality included transarterial chemoembolization, 
transarterial radioembolization, hepatic artery infusion chemothera-


























































































Fig. 2. Cumulative probabilities of a recurrence of hepatocellular carcinoma (HCC) according to the last HCC treatment durability (A) and the total 
duration of the HCC treatment (B) in the multicenter cohort.
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Meanwhile, even if short last HCC treatment durabil-
ity is an independent risk factor for HCC recurrence, it 
is difficult to interpret the finding that the delayed DAA 
therapy reduces the risk of HCC recurrence. Two recent 
meta-analyses and a large cohort study found that DAA 
therapy was not associated with an increased risk of HCC 
recurrence.18,24,25 One of the meta-analyses pointed out that 
factors associated with HCC recurrence included a his-
tory of prior HCC recurrence and a short interval between 
HCC CR and initiation of the DAA treatment. The authors 
concluded that HCC recurrence rate was acceptable after 
the DAA therapy, particularly if the latter was delayed at 
least 6 months after HCC CR.24 However, a recent large 
cohort study that defined HCC recurrence time based on 
the timing of HCC CR showed that commencement of 
DAA therapy within 6 months of CR was not a risk factor 
for overall or an early HCC recurrence.25 As mentioned 
above, there has been a debate on the optimal timing of 
starting DAA treatment after acquiring CR. Several studies 
calculated the time to HCC recurrence from the start of 
the DAA therapy, leading to an immortal time bias.24 The 
present study also cannot be free from this bias. Therefore, 
we could not clearly suggest an appropriate time point 
about initiation of DAA therapy for patients with HCC 
who achieved CR. It is more appropriate to describe “short 
last HCC treatment durability” rather than “short interval 
between last HCC treatment and DAA therapy” as a risk 
factor for HCC recurrence. 
Other well-known risk factors for HCC development, 
including liver cirrhosis, diabetes mellitus, male gender, 
and old age, were not associated with an increased HCC 
recurrence.26-29 Our findings were found to be in line with 
Table 5. Risk Factor Analysis for HCC Recurrence in the HIRA Cohort
Risk factor









HR 95% CI p-value
Age, yr 66.8±9.8 67.4±8.9 0.867
Male sex 267 (63.7) 68 (63.6) 0.903
Diabetes mellitus 200 (71.6) 71 (66.4) 0.160
Liver cirrhosis 360 (85.9) 98 (91.6) 0.103 
HCC treatment using noncurative modality* 290 (69.2) 96 (89.7) <0.001† 0.75 0.42–1.33 0.330
Last HCC treatment using noncurative modality* 244 (58.2) 93 (86.9) <0.001† 3.73 1.87–7.43 <0.001†
HCC treatment duration (≥18 mo) 100 (23.9) 44 (41.1) <0.001† 1.74 1.16–2.60 0.006†
Last HCC treatment durability (<12 mo) 236 (56.3) 91 (85.0) <0.001† 3.34 1.95–5.71 <0.001†
Data are presented as the mean±SD or number (%). 
HCC, hepatocellular carcinoma; HIRA, Health Insurance Review and Assessment; HR, hazard ratio; CI, confidence interval. 
*Noncurative modality included transarterial chemoembolization, transarterial radioembolization, hepatic artery infusion chemotherapy, sorafenib 






















































































Fig. 3. Cumulative probabilities of a recurrence of hepatocellular carcinoma (HCC) according to the last HCC treatment durability (A) and the total 
duration of the HCC treatment (B) in the nationwide Health Insurance Review and Assessment Service cohort.
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a study with 59 patients who underwent a DAA therapy 
after HCC treatment who showed no significant differ-
ences in these factors between patients with and without 
HCC recurrence.15 While liver cirrhosis, diabetes mellitus, 
male gender, and old age are well-established risk factors 
for HCC development in patients with chronic hepatitis C, 
their role in HCC recurrence is unclear. This may be due to 
the differences in follow-up period between patients with a 
new and a recurrent HCC. 
A few studies have suggested that patients with HCC 
are resistant to the DAA therapy.12-14 In 2017, Beste et al.13 
reported that, of the 17,487 recipients of an HCV treat-
ment, the overall SVR12 rate was 91.1% in the non-HCC 
group and 74.4% in the HCC group. In another study, the 
SVR12 rate was 79% and 88% in patients with and without 
HCC, respectively.14 There are several proposed theories 
explaining the observation of relatively low SVR12 rates in 
patients with HCC. HCC may act as a reservoir for HCV 
replication.12,30 Moreover, the HCC cells, which are mainly 
supplied by branches of the hepatic artery,31 and exhibit 
downregulated levels of the membrane transporters essen-
tial for the DAA uptake, such as OATP1B1,12,32 may have 
limited penetration of DAAs. Herein, the overall SVR12 
rate after DAA therapy was 88%, which increased to 91.7% 
in patients who underwent the DAA therapy within 6 
months of the last HCC treatment. Considering the kind 
of DAA therapy in the current study (Table 1), an overall 
SVR12 rate of 88% is satisfactory. Further studies with 
more potent DAAs will be needed to confirm the efficacy 
of DAA therapy in patients with HCC.
The current study has several limitations. First, it did 
not include a control group, which made it difficult to 
ascertain whether DAA therapy itself could increase the 
risk of HCC recurrence. Second, this study included 46 
patients who had received noncurative modality as last 
treatment. To secure as many patients as possible, patients 
with noncurative modality were also included. Consider-
ing this limitation, a subgroup analysis was conducted on 
54 patients treated with curative method. Subgroup analy-
sis showed that last HCC treatment durability less than 12 
months was not significantly associated with HCC recur-
rence but tended to increase risk (p=0.058). Further, we 
did not define the HCC recurrence time based on the tim-
ing of CR. The purpose of the current study was to define 
risk factors for HCC recurrence after the DAA therapy; 
thus, we started the follow-up after commencement of the 
DAA therapy. Additionally, patients treated with heter-
ogenous methods were recruited, and it was not possible 
to confirm CR in the HIRA cohort. As very few patients 
with an HCV-related HCC have been treated with DAAs 
in South Korea, we sought to recruit as many participants 
as possible. We included patients who obtained a CR in the 
multicenter cohort, and confirmed the risk factors in the 
HIRA cohort, although the two cohorts partly overlapped.
In conclusion, the efficacy of DAA therapy was found 
to be acceptable in patients with an HCV-related HCC. 
However, short last HCC treatment durability before the 
DAA therapy (<12 months) was associated with HCC 
recurrence. This finding suggests that the last HCC treat-
ment response durability is an important predictor of HCC 
recurrence. 
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